Andere talen Tarsus Pharmaceuticals, Inc.

Aandelen

TARS

US87650L1035

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
36,85 ^USD	+6,41%		+15,01%	+81,98%

24/04	BioPharma Credit gaat USD100 miljoen lenen aan Tarsus Pharmaceuticals	AN
27/03	Grand Pharmaceutical Group Limited gaat een strategische samenwerkingsovereenkomst aan voor productintroductie met LianBio Development (HK) Limited en Tarsus Pharmaceuticals, Inc.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024	01/05
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals	24/04
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals	24/04
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon	23/04
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon	23/04
Tarsus Pharmaceuticals, Inc. Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-Dilutive Financing Commitment from Pharmakon	23/04
Tarsus Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding	19/04
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	27/03
Tarsus Pharmaceuticals : Corporate Presentation	19/03
Tarsus to Participate at Upcoming Investor Conferences	05/03
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis	05/03
Tarsus Pharmaceuticals Prices $100 Million Public Offering	01/03
Tarsus Announces Pricing of $100.0 Million Public Offering	01/03
Tarsus Announces Proposed $100.0 Million Public Offering	29/02
Tarsus Pharmaceuticals' Q4 Net Loss Widens, Revenue Increases	27/02
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q4 Revenue $13.1M, vs. Street Est of $5.9M	27/02
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements	27/02
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tarsus Pharmaceuticals, Inc.

Aandelen

TARS

US87650L1035

Andere talen

Filters